Imunon’s (IMNN) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Imunon (NASDAQ:IMNN) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a $29.00 target price on the stock.

Other research analysts have also issued research reports about the company. EF Hutton Acquisition Co. I raised Imunon to a “strong-buy” rating in a report on Monday, September 23rd. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Imunon in a research note on Wednesday, December 11th.

Imunon Trading Down 0.5 %

IMNN stock traded down $0.00 during mid-day trading on Thursday, hitting $0.85. The stock had a trading volume of 674,708 shares, compared to its average volume of 908,321. The stock has a market capitalization of $12.33 million, a price-to-earnings ratio of -0.45 and a beta of 2.12. The company has a fifty day moving average of $0.87 and a 200 day moving average of $1.08. Imunon has a 1-year low of $0.48 and a 1-year high of $3.65.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.